BrightSpring Health Services, Inc. Common Stock

BrightSpring Health Services, Inc. Common Stock (BTSG) Market Cap

BrightSpring Health Services, Inc. Common Stock has a market capitalization of $9.15B.

Financials based on reported quarter end 2025-12-31

Price: $47.27

β–² 1.47 (3.21%)

Market Cap: 9.15B

NASDAQ Β· time unavailable

CEO: Jon Rousseau

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2024-01-26

Website: https://www.brightspringhealth.com

BrightSpring Health Services, Inc. Common Stock (BTSG) - Company Information

Market Cap: 9.15B Β· Sector: Healthcare

BrightSpring Health Services, Inc. operates a home and community-based healthcare services platform in the United States. The company's platform focuses on delivering pharmacy and provider services, including clinical and supportive care in home and community settings to Medicare, Medicaid, and insured populations. It serves patients through clinical providers and pharmacists. BrightSpring Health Services, Inc. was formerly known as Phoenix Parent Holdings Inc. and changed its name to BrightSpring Health Services, Inc. in May 2021. The company was founded in 1974 and is based in Louisville, Kentucky.

Analyst Sentiment

85%
Strong Buy

Based on 16 ratings

Analyst 1Y Forecast: $40.85

Average target (based on 2 sources)

Consensus Price Target

Low

$36

Median

$45

High

$55

Average

$45

Downside: -4.0%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ BRIGHTSPRING HEALTH SERVICES INC (BTSG) β€” Investment Overview

🧩 Business Model Overview

BrightSpring Health Services Inc (BTSG) is a leading provider of home and community-based healthcare and pharmacy services in the United States. The company operates through a diversified platform offering essential services to individuals with complex, chronic, and specialized needs. BTSG serves a broad spectrum of populations, including the elderly, individuals with intellectual and developmental disabilities (IDD), behavioral health conditions, and those requiring chronic and specialty pharmaceutical therapies. The business is structured to deliver integrated, value-based care across the continuum β€” from personal caregiving and nursing to pharmacy dispensation β€” through a network of skilled caregivers, clinicians, and a scaled technology infrastructure. The company partners with government agencies, managed care organizations, and commercial payers to provide care solutions that aim for optimal outcomes, compliance, and cost efficiency.

πŸ’° Revenue Streams & Monetisation Model

BTSG generates revenue through several synergistic channels aligned with its core service offerings: - **Home and Community-Based Services:** The company delivers caregiving, personal assistance, skilled nursing, and therapy services in home and residential settings. Reimbursements are primarily sourced from Medicaid, Medicare, and state/local contracts, often structured as fee-for-service or managed care arrangements. - **Pharmacy Solutions:** Through its specialized (including long-term care and behavioral health) and home infusion pharmacy operations, BTSG dispenses complex pharmaceutical therapies and medications to high-need populations. Revenue is generated via pharmacy benefit managers, government programs, and direct contracts. - **Case Management and Behavioral Health Services:** These segments involve care coordination, behavioral therapy, and mental health support, contracted or reimbursed under various government and commercial health plans. - **Advisory and Cross-Sell Synergies:** By integrating multiple touchpoints of the patient journey, BTSG can cross-sell additional services to existing clients, creating stickier revenue and boosting lifetime value. The monetization model is predominantly reimbursement-driven, subject to negotiated rates, per-capita contracts, or capitated payments, with an increasing proportion of value-based contracting as payers seek better quality and cost alignment.

🧠 Competitive Advantages & Market Positioning

BTSG holds a defensible position in the healthcare services landscape, leveraging several key competitive advantages: - **Integrated Service Platform:** The ability to deliver both pharmacy and care management in-home and community-based settings creates operational efficiencies, enhances data flow, and improves clinical outcomes, making BTSG a compelling partner for payers and policymakers. - **Scale and Geographic Diversity:** BTSG operates across a large number of states, serving a diverse and complex client base, which provides risk diversification and purchasing power with suppliers. - **Expertise in High-Need, Underserved Populations:** The company’s deep experience with populations requiring long-term care, IDD, and behavioral health services serves as a barrier to entry and differentiates it from more commoditized providers. - **Compliance and Regulatory Acumen:** A strong track record in adhering to complex federal and state regulations mitigates operational risk and builds trust with payers and regulators. - **Technology Enablement:** Investment in care coordination and pharmacy technology platforms enhances clinical insights, drives quality of care, and enables scalable growth.

πŸš€ Multi-Year Growth Drivers

Several secular and company-specific growth catalysts underpin BTSG's long-term outlook: - **Aging Population:** Demographic tailwinds from the rapidly expanding elderly population in the United States are driving increased demand for home and community-based care. - **Healthcare Cost Pressures:** Payers and government programs are migrating care away from high-cost institutional settings to lower-cost (yet clinically robust) home-based alternatives, directly supporting BTSG’s core offerings. - **Value-Based Care Emergence:** The industry-wide shift toward value-based reimbursement aligns with BTSG’s outcome-focused, integrated model, positioning it for volume and margin upside as these models scale. - **Increased Chronic Disease Prevalence:** Growing incidences of chronic, complex medical conditions require ongoing care coordination and specialized pharmacy services. - **Acquisitions and Market Consolidation:** Significant fragmentation exists in BTSG’s core markets, creating opportunity for growth via targeted M&A, leveraging the company's scale and integration capability. - **Cross-Selling and Vertical Integration:** Enhanced cross-selling between care and pharmacy services increases wallet share and strengthens client retention.

⚠ Risk Factors to Monitor

Investors should remain mindful of several notable risks inherent to BTSG’s business model and sector: - **Regulatory and Reimbursement Risk:** The company is highly dependent on government reimbursement (particularly Medicaid and Medicare). Any change in policy, reimbursement rates, or eligibility criteria can materially affect earnings. - **Workforce and Talent Availability:** BTSG’s services are labor-intensive; shortages in skilled caregivers, wage pressures, or high turnover could constrain growth or compress margins. - **Competitive Threats:** The healthcare services market remains competitive, with both national and regional players, as well as evolving β€œat-home” care platforms from health systems or technology-driven disruptors. - **Execution Risks on Integration:** BTSG’s multi-service offering and any M&A activity can lead to operational complexities or integration risks, impacting efficiency and profitability. - **Technology and Compliance:** Data security breaches, system downtime, or compliance failures in sensitive healthcare data can incur significant reputational or financial liability.

πŸ“Š Valuation & Market View

BTSG is typically valued relative to peer home health, pharmacy services, and healthcare outsourcing companies on a basis of EBITDA multiples, EV/Sales, and free cash flow yield, with market participants factoring in the company’s growth rates, margin profile, and geographic/segment diversification. Its integrated service platform and above-average exposure to secular growth drivers may justify a premium to more narrowly focused peers, particularly as the company demonstrates ability to scale value-based contracts and cross-sell across segments. However, any adverse changes in reimbursement or margin headwinds unique to its mix of high-need populations could warrant caution or sector-level discounts. The fragmented nature of its end markets provides sustained M&A potential, which, if executed prudently, can be accretive to long-term intrinsic value.

πŸ” Investment Takeaway

BrightSpring Health Services Inc offers a compelling long-term investment thesis predicated on favorable demographic tailwinds, a scaled and integrated platform catering to high-growth segments of the healthcare continuum, and multi-lever growth opportunities through both organic expansion and acquisition. The company’s ability to navigate regulatory complexity, sustain operational excellence, and scale value-based, outcome-driven models provides it with clear differentiation in a dynamic industry. Key risks remain around government policy and workforce dynamics, but for investors seeking exposure to the long-term transformation of care delivery β€” especially the home and community-based care revolution β€” BTSG merits ongoing consideration as both a consolidator and innovator in this evolving space.

⚠ AI-generated β€” informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"Revenue and EPS: latest quarter (2025-12-31) revenue was $3.55B and EPS was $0.46. Net income was $77.1M. QoQ trends: Revenue grew 6.5% vs 2025-09-30 ($3.33B β†’ $3.55B). Net income improved 38.0% QoQ ($55.8M β†’ $77.1M), and profitability strengthenedβ€”net margin rose to ~2.17% from ~1.67% in the prior quarter, continuing an improving pattern over the last four quarters (net margin moved from ~0.90–1.03% earlier in 2025 to 2.17% most recently). YoY trends: YoY comparisons for revenue and net income are not possible from the provided dataset because prior-year (e.g., 2024-12-31) quarters are not included. Cash flow: Free cash flow (FCF) rebounded sharply to ~$289M in the latest quarter from ~$92M in the prior quarter, supporting earnings quality. No dividends were paid. Shareholder returns: With a +169% 1-year price change and strong recent momentum (also +54% over 6 months), total shareholder return is primarily being driven by capital appreciation. Balance sheet resilience appears to be improving, with total equity rising to ~$1.89B and total assets increasing over the last four quarters."

Revenue Growth

Good

QoQ revenue increased 6.5% in the latest quarter ($3.33B β†’ $3.55B). YoY revenue growth could not be calculated because prior-year quarters were not provided.

Profitability

Good

Net income improved 38.0% QoQ ($55.8M β†’ $77.1M). Net margin expanded to ~2.17% from ~1.67% prior quarter, improving versus earlier quarters in 2025. EPS rose to $0.46 from $0.19 QoQ.

Cash Flow Quality

Strong

FCF strengthened materially to ~$289M in the latest quarter from ~$92M prior quarter. Dividends are zero, so cash flow is being retained to support growth/leverage dynamics.

Leverage & Balance Sheet

Positive

Total assets and equity increased over the last four quarters (equity ~$1.69B β†’ ~$1.89B). Net debt remains elevated (~$2.75B latest), but equity growth suggests improving balance-sheet resilience.

Shareholder Returns

Strong

Strong total shareholder return driven by price momentum: +169% 1-year and +54% 6-month. No dividend yield is reported; buybacks not provided.

Analyst Sentiment & Valuation

Positive

Latest P/E is ~24.6. Consensus price target is ~$45.4 versus current price ~$46.01 (slightly below/near-term fair value).

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

BrightSpring delivered strong Q4 and FY25 results, exceeding guidance with broad-based growth led by specialty/infusion and home health, margin expansion, and notable deleveraging. Strategic actions include the pending divestiture of Community Living to fund debt reduction and the accretive acquisition of Amedisys/LHC branches. Quality metrics remain industry-leading, and 2026 guidance calls for double-digit revenue and outsized EBITDA growth, supported by LDD launches and operational efficiencies. Minor headwinds from a customer bankruptcy in home & community pharmacy are acknowledged but embedded in the outlook.

Growth

  • Q4 revenue +29% YoY to ~$3.6B; Q4 adjusted EBITDA +41% YoY to $184M
  • FY25 revenue $12.9B (+28% YoY); Pharmacy Solutions $11.4B (+31%); Provider Services $1.5B (+11%)
  • FY25 adjusted EBITDA $618M (+34% YoY); margin 4.8% (+20 bps)
  • Specialty/infusion Q4 revenue $2.6B (+43% YoY); specialty/infusion scripts +30% YoY
  • Provider Services Q4 revenue $394M (+13% YoY); segment EBITDA margin 16.4% (+50 bps)
  • Home health care revenue +19% YoY; average daily census +15% to ~35,000

Business Development

  • Divesting Community Living; expected close end Q1 2026 with ~$715M net after-tax proceeds
  • Acquired 107 Amedisys/LHC branches (Dec 1/31, 2025) for $239M, funded with cash; assets generated $345M FY25 pro forma revenue
  • 24 LDD launches in 2025 (5 in Q4); LDD portfolio now 149; expecting 16–20+ LDD launches in next 12–18 months
  • De novo expansions and small tuck-in acquisitions across segments
  • Selected as preferred specialty partner for new innovative infusible therapies

Financials

  • Q4 Pharmacy Solutions revenue $3.2B (+32% YoY); home & community pharmacy $593M (-1% YoY)
  • Q4 gross profit $413M (+22% YoY); FY25 gross profit $1.5B (+20% YoY)
  • Adjusted EPS: $0.33 (Q4); $1.00 (FY25)
  • FY25 cash from operations $490M
  • Leverage reduced to 2.99x at 12/31/2025 (from 4.16x at 12/31/2024)

Capital & Funding

  • Community Living divestiture proceeds (~$715M) planned primarily for debt paydown
  • Amedisys/LHC acquisition ($239M) fully funded with cash on hand
  • Ongoing procurement and technology initiatives to enhance efficiency and margins
  • Strengthened balance sheet with lower leverage and higher operating cash flow

Operations & Strategy

  • Streamlining to core patient populations; integration of Amedisys/LHC into home health and hospice footprint
  • Process, technology, and automation initiatives underway for 2026 efficiency gains
  • Enhanced go-to-market in home & community pharmacy; exiting uneconomic customers
  • Investing in home-based primary care aligned with ACO payment strategies
  • Operational improvements driving improved infusion profitability
  • High quality metrics across businesses (e.g., 91% of home health branches β‰₯4 stars; 99.4% timely initiation; hospice CAHPS 87%)

Market & Outlook

  • 2026 guidance: revenue +~14% YoY (midpoint); adjusted EBITDA +~25% YoY (midpoint)
  • Includes ~$30M 2026 EBITDA contribution from Amedisys/LHC assets
  • Home health positioned to reduce ER/hospitalizations and mortality; under-penetration (35% of referred patients not receiving care) seen as growth opportunity
  • Investor Day scheduled for March 17 to detail long-term strategy and drivers

Risks Or Headwinds

  • Home & community pharmacy impacted by bankruptcy of a large customer and exits of uneconomic customers (Q4 revenue -1% YoY)
  • Customer bankruptcy process ongoing; scenarios contemplated in guidance
  • Execution risks around integration of acquired branches and scaling new LDD launches

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the BTSG Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (BTSG)

Β© 2026 Stock Market Info β€” BrightSpring Health Services, Inc. Common Stock (BTSG) Financial Profile